DNLDX
Price
$62.70
Change
-$0.19 (-0.30%)
Updated
Sep 20 closing price
VIMSX
Price
$71.38
Change
-$0.13 (-0.18%)
Updated
Sep 20 closing price
Ad is loading...

DNLDX vs VIMSX

Header iconDNLDX vs VIMSX Comparison
Open Charts DNLDX vs VIMSXBanner chart's image
BNY Mellon Active MidCap A
Price$62.70
Change-$0.19 (-0.30%)
VolumeN/A
CapitalizationN/A
Vanguard Mid Cap Index Investor
Price$71.38
Change-$0.13 (-0.18%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
DNLDX vs VIMSX Comparison Chart
Loading...
VS
DNLDX vs. VIMSX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLDX is a Buy and VIMSX is a Buy.

FUNDAMENTALS
Fundamentals
VIMSX has more cash in the bank: 172B vs. DNLDX (461M). VIMSX pays higher dividends than DNLDX: VIMSX (1.38) vs DNLDX (0.63). DNLDX was incepted earlier than VIMSX: DNLDX (40 years) vs VIMSX (26 years). DNLDX is a more actively managed with annual turnover of: 57.46 vs. VIMSX (13.00). DNLDX has a lower initial minimum investment than VIMSX: DNLDX (1000) vs VIMSX (3000). VIMSX (25.11) and DNLDX (24.15) have marching annual gain over last year. VIMSX return over 5 years is better than : 56.75 vs. DNLDX (19.75).
DNLDXVIMSXDNLDX / VIMSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence40 years26 years-
Gain YTD11.33012.55790%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets461M172B0%
Annual Yield % from dividends0.631.3846%
Returns for 1 year24.1525.1196%
Returns for 3 years-5.559.82-57%
Returns for 5 years19.7556.7535%
Returns for 10 years20.81128.2116%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INSE10.090.15
+1.51%
Inspired Entertainment
FOUR86.901.01
+1.18%
Shift4 Payments
CALT40.00-0.16
-0.40%
Calliditas Therapeutics AB
BCE35.04-0.15
-0.43%
BCE
ACST2.70-0.08
-2.88%
Acasti Pharma